Alzheimer’s drug Leqembi rejected by EU drug regulator
![](/46/pdcnewsitem/12/50/03/Heading%20image%20(17).png)
The European Medicine’s Agency (EMA), the drug regulator for the EU, rejected Eisai and Biogen’s Alzheimer’s drug product Leqembi, citing the drug’s slowing of cognitive decline did not outweigh the risk of serious brain swelling.
Leqembi is currently approved for use in the US, China, Hong Kong, Japan, and South Korea. If it had been approved, it would have been the first drug approved in Europe to treat Alzheimer’s disease, not simply its symptoms. The drug is administered as an infusion twice a month, and operates by removing sticky clumps of amyloid beta protein. This protein is believed to be a hallmark of the neurodegenerative disease and is the target of several clinical drug trials. Leqembi demonstrated a rate of slowing cognitive decline by 27% in early Alzheimer’s patients when compared with a placebo.
While disappointing those affected by the disease such as the non-profit Alzheimer’s Europe, the EMA have cited their analysis from the Committee for Medicinal Products for Human Use. Three primary reasons stand for the decision. The EMA also pointed to cases of a specific type of brain swelling and bleeding called ARIA, that led to some hospitalisations of patients during the clinical trials.
Despite disappointment from certain groups, experts state that Leqembi was unlikely to have been widely used in Europe even if it had been approved. In the US, the drug has faced supply chain bottlenecks due to its twice-monthly administration requirements, as well as regular brain scans for patients. These requirements are leading regulators to consider where to shift limited resources including time, money, and trained staff, and what guidance should be created on clinically meaningful benefits in treating Alzheimer’s disease.
Earlier this year, Eli Lilly’s Alzheimer’s treatment Kisunla received US FDA approval and is currently being reviewed by the EMA as of the publication date of this article. Analysts are sceptical regarding Kisunla’s approval in the EU after the EMA’s rejection of Leqembi.
Source:
Alzheimer’s drug from Eisai and Biogen rejected in Europe [Accessed July 30, 2024] https://www.reuters.com/business/healthcare-pharmaceuticals/eu-medicines-regulator-rejects-eisai-biogen-alzheimers-drug-2024-07-26/
Related News
-
News Second obesity drug candidate from Roche shows early trial success
Following from its purchase of Carmot Therapeutics, Roche have announced positive early-stage trial success for its second obesity drug candidate acquired from Carmot Therapeutics. -
News Tumour microproteins could provide basis for cancer vaccines
A recent study published in Science Advances has identified a set of microproteins produced exclusively in liver tumours, which may provide a clear target for the development of a cancer vaccine. -
News Reworked once-daily weight-loss pill from Pfizer to progress
American pharmaceutical giant Pfizer have continued with a reworked version of their weight-loss pill danuglipron, progressing with a once-daily version of the pill. -
News CPHI Online Trend Report: what is pharmaceutical packaging really costing the industry?
The latest CPHI Online Trend Report dives into what it really costs to develop, manufacture, and deploy pharmaceutical packaging that balances sustainability concerns, patient safety, and drug efficacy. -
News Eli Lilly’s Alzheimer’s drug receives approval from US FDA
After facing several hurdles on its path to approval last year, Eli Lilly’s donanemab treatment for early Alzheimer’s, brand name Kisunla, received US FDA approval this past week. It is the second therapy for slowing the progression of Alzh... -
News This week in GLP-1 drug headlines: Manufacturing investment and new market launches
As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l... -
News Women in Pharma: Regulating equity across regional borders
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Viral marketing for B2B pharma businesses: a CPHI Online case study
Discover how a Chinese chemical manufacturing company went viral on TikTok, and what their viral success means for the future of B2B digital marketing for the wider pharmaceutical industry and supply chain.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance